Press Releases
GlaxoSmithKline presents positive data for Anoro Ellipta in COPD patients who remained symptomatic on tiotropium
GlaxoSmithKline and Innoviva Inc announced results from data presented at the American Thoracic Society (ATS) 2016 International Conference investigating the efficacy and safety of...
Press Releases
GlaxoSmithKline presents new data from Breo Ellipta SUMMIT study in patients with COPD at ATS Conference
GlaxoSmithKline and Innoviva, Inc announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from...
Press Releases
Amgen Inc Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients
New Analysis From Phase 3 Trial of Kyprolis® (Carfilzomib) Combination Treatment in Relapsed Multiple Myeloma Patients With Early Disease ProgressionPhase 1/3 MASTERKEY-265 Study Abstracts...
News
Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting
First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line following Glivec®* First genomic...
News
Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference
Valeant Pharmaceuticals International, Inc. announced that Mr. Joseph Papa, Chairman and Chief Executive Officer, will participate at the UBS Global Healthcare Conference to be...
Press Releases
AstraZeneca reports the positive Top-Line Results from the Benralizumab Phase III Programme in Severe Asthma
Kyowa Hakko Kirin Co Ltd announced that AstraZeneca obtained the positive top-line results that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was...
Press Releases
FDA approves For Eisais Anticancer Agent Lenvima In Combination With Everolimus as Treatment For advanced Renal Cell Carcinoma
Eisai Co Ltd announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read